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O
ne of the surprises that arose 
from the Human Genome Proj-
ect is that there are far fewer hu-
man genes than anyone had guessed. The 
complexity and diversity of the human 
proteome is generated in part by alterna-
tive splicing—once thought to be a rela-
tively rare event, but now believed to af-
fect approximately 75% of our genes. 
Ladd is one of a growing breed of investi-
gators that examines how alternative splic-
ing events shape the developing embryo.
Factors that control alternative splic-
ing, such as the CELF proteins that Ladd 
helped to identify (1, 2), are starting to be 
thought about in the same way as tran-
scription factors—as key regulators of 
gene expression programs. 
Researchers are thus in-
vestigating how the factors 
themselves are develop-
mentally regulated, how 
they work, and what tran-
scripts they target for 
splicing. Ladd made great 
headway in tackling these 
questions during her post-
doc studies at the Baylor 
College of Medicine in 
Houston, Texas (1–5). 
Now, Ladd continues to ask and answer 
the questions of alternative splicing regu-
lation in her own laboratory at the Cleve-
land Clinic in Ohio.
A SURE START
As a kid, what did you want to be when 
you grew up?
I pretty much always wanted to be a biolo-
gist. I was a nerdy little kid, very interested 
in science. I loved animals and plants and 
going to the zoo and the science museum; 
those were my favorite places. I think the 
fi  rst time I really thought about what I 
wanted to do when I grew up was when I 
was in seventh grade.
It was the fi  rst year we studied biology. 
And I had a really fantastic biology teach-
er named Mr. Keyes. The second week of 
school I came home and announced to my 
entire family that I was going to be a re-
search biologist!
And that was that! Where did you go to 
university?
I did my undergrad at the University of 
Wisconsin in Madison and studied mo-
lecular biology.
At what stage did you know that you 
deﬁ  nitely wanted to do a PhD?
Actually, I had it in my mind right at the 
beginning.
In seventh grade?
[Laughs] Well, maybe not from seventh 
grade, but right from the beginning of col-
lege. I got a job working in a laboratory 
when I was an undergrad and worked 
there for several years, and I really loved 
it. I loved interacting with the graduate stu-
dents and postdocs, and I thought, “This 
thing’s really cool, I want to do that.”
What made you choose the University 
of Arizona for your PhD?
It was more of a personal decision than a 
professional one. I had never been any-
where outside the Midwest, and I thought 
this could be a big adventure, to move 
someplace so far away and so different 
from Wisconsin.
They were very smart; they brought 
me down for my interview in January. It 
was the coldest winter on record back 
home, it was 50 below at the airport when 
I left, and when I arrived in Tucson, it 
was 72 degrees. It was clever, because 
then I moved to Tucson in August, and it 
was 116 degrees! A little less enjoyable.
Your PhD was with Parker Antin. 
What was it about developmental 
biology, and speciﬁ  cally heart 
development that captured you?
The heart is the fi  rst organ that forms in the 
embryo, and the idea that an embryo that 
looks like almost nothing at the time—just 
a few thousand cells—can create a func-
tioning heart was fascinating. The heart is 
particularly interesting because as it’s 
forming and developing, it already has to 
be working. It’s constantly pumping, and 
yet undergoing morphogenesis and differ-
entiation at the same time.
APPEAL OF THE ALTERNATIVE
How did you get into studying splicing?
When I was thinking about a postdoc, I 
was looking at other developmental biol-
ogy laboratories but felt that I would just 
be looking at the same kind of problems 
in another tissue. I wanted instead to go 
into a different fi  eld so that I could then 
come back to developmental biology from 
a new angle.
Splicing was chosen by accident. I was 
at a Gordon Conference on muscle devel-
opment with Parker, and at the meeting 
we hung out with Tom Cooper, who had 
done his postdoc in the same laboratory as 
Parker. I had a lot of great conversations 
with Tom, and then after the meeting 
Parker sent an email to Tom and said, 
“You know, Andrea’s looking for a post-
doc.” So Tom contacted me, and we started 
talking. I don’t think I would’ve thought 
of looking at alternative splicing if it 
hadn’t been for that.
Ladd identiﬁ  es alternative splicing regulators and examines how they 
shape the heart during development.
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But once we started talking, I thought, 
“You know, this is really fascinating. I had 
no idea alternative splicing was so preva-
lent or so important.” I thought it was 
something I could go after, because I didn’t 
think the developmental biology commu-
nity had really looked at this.
What was your project in Tom’s 
laboratory?
When I joined the laboratory, they had 
just identifi  ed a new family of splicing 
factors called the CELF proteins, which 
stands for CUG-BP and ETR-3–like fac-
tors—those were the fi  rst two members of 
the family to be described.
I started out doing some Western blots 
and saw that the expression patterns of 
CELF proteins were very dynamic during 
development. A lot of researchers in the 
alternative splicing community looked at 
how a gene was spliced one way in mus-
cle cells, and another way in neurons. But 
there hadn’t been many studies into what 
happens within the same cell type over 
time. I found evidence to suggest that 
CELF protein expression changes drive 
the developmental transition between fe-
tal and adult patterns of splicing in the 
developing heart.
How do CELF proteins direct the 
splicing machinery to control 
alternative splicing?
That’s a great question. Actually, very lit-
tle is known about that. We know they 
bind to the RNA, and that they have to 
bind to the RNA to affect splicing. But 
how precisely they’re communicating 
with the basal splicing machinery is not 
well understood.
What else are you looking at?
We’re starting to look at another family of 
splicing regulators called the muscleblind-
like proteins, which act on many of the 
same subset of targets as the CELF pro-
teins but, at least in some cases, have been 
shown to be antagonistic.
We have preliminary data that both the 
CELF and the muscleblind-like protein 
family are very dynamic during embry-
onic heart development. And so we think 
that they’re involved in developmental 
stage-specifi  c alternative splicing control.
My guess is that probably most, if not 
all the different splicing factor families 
are developmentally regulated in different 
tissues, in much the same way that tran-
scription factors are.
And presumably they each have a 
distinct subset of targets.
Right. Each protein or each family of splic-
ing regulators would affect different subsets 
of targets, and some of those subsets may 
overlap, and some may be very distinct.
You’ve identiﬁ  ed six of these CELF 
proteins. Do you know all of their targets?
That’s actually one of the big questions 
that we have now. Only a very small 
number of targets have been identifi  ed, and 
we think there are probably many more. 
We’re now trying to identify the others.
Are you working on any other projects?
I think the big, overriding question that 
we really want to answer is, what are the 
consequences of these splicing programs 
for development? Not just how is splicing 
regulated, but why is it important?
So we’re using a variety of whole em-
bryo, primary cell, and embryonic explant 
assays to go in and manipulate the splic-
ing factors and see what effects we’re 
having on morphogenetic processes.
THE RIGHT FIT
What made you choose Ohio?
It was a combination of things. On a profes-
sional level, the Cleveland Clinic is really a 
top-notch place. It’s got great resources, it’s 
got great people. And scientifi  cally, it was a 
great fi  t. Our work is sort of a combination 
of cardiovascular, developmental, and RNA 
biology, and that’s an unusual combination. 
But here in Cleveland, between the Cleve-
land Clinic and Case Western Reserve Uni-
versity, there’s actually a huge RNA com-
munity. And at the Cleveland Clinic there’s 
a huge cardiovascular biology community.
Then on a personal level, I just really 
liked Ohio. I really wanted to move north 
after living in Arizona and Texas. I discov-
ered the southern climate doesn’t really 
agree with me, and I wanted to go back to 
a place that had a change of seasons and 
had a real winter, and snowed on Christ-
mas. I really love the midwestern culture.
Are you enjoying life as a Principle 
Investigator?
It’s fun. It’s kind of stressful. When I left 
Tom’s laboratory, I remember he told me 
that being a PI is like being a parent. It’s 
one of those things that, if you had any 
idea going in how much work it would be 
or how hard it would be 
or how stressful it would 
be, you might not want to 
do it. But once you’re 
there and you’re doing it, 
it’s so rewarding, you’re 
glad you did. I don’t know 
about being a parent, but 
as a PI, I’d say that’s com-
pletely true. 
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One of the CELF family of alternative splicing 
regulators (purple), expressed in a chick 
embryo’s heart.
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